Eikon Therapeutics targets $317M raise in IPO

Eikon Therapeutics, an oncology and neuroscience biotech that has raised more than $1 billion, is seeking up to $317 million in its IPO.

Why it matters: At the midpoint, the IPO values Eikon at about $857 million, underscoring a steep markdown in valuation.